gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ACADHealthcarePharmaceuticals

Acadia Pharmaceuticals Inc. (ACAD)

$21.47+4.38%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$21.47▼ 1.74% in range
Nov 4, 2025Low $18.62 · High $30.57Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Acadia Pharmaceuticals closed at $21.47 on Nov 4, up 4.38%, 29.8% below its 52-week closing high. Volume of 4.7M shares was 3.08× its 20-day average (well above normal).

Split-adjusted performance: +8.8% over one month, -0.0% over six months, -4.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $307.96M, up 16.4% from a year earlier, with a net margin of 10.2%.

Short interest was 9.1M shares at the Oct 15 settlement, up 9.9% from the prior report (7.1% of float, 4.6 days to cover).

Market cap$3.70B172.3M shares
Revenue · quarter$308.0M+16.4% YoY
Diluted EPS$0.18+12.5% YoY
P/E · TTM9.7×P/S 3.2×
Net margin10.2%Gross 90.8%
Dividend yieldNone
52-week range18.62 – 30.57−29.8% from high
Volume4.7M3.08× 20-day avg
Volatility · 60d44.9%Annualised
Short % of float7.1%4.6 days to cover
Net cash$956.5MCash $956.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +5.7%1M +8.8%3M −24.5%6M 0.0%YTD −19.6%1Y −4.0%3Y −3.4%5Y +22.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum72
Revenue growth62
Net margin80
Value (low P/E)71
Size87

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short9.1M+9.9% vs prior
Days to cover4.6Settled Oct 15
% of float7.1%
Short vol. 10d42.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ACADAcadia Pharmaceuticals$21.47+4.38%0.0%+16.4%10.2%9.7$3.70B
IRONDisc Medicine$83.28+2.61%+21.3%———$3.70BCompare
AMLXAmylyx Pharmaceuticals$29.40+0.68%+83.1%———$3.69BCompare
PBLSParabilis Medicines$30.36+3.79%——−45239.9%—$3.75BCompare
OGNOrganon &$13.83−0.14%+3.1%−1.7%10.4%17.1$3.63BCompare
XENEXenon Pharmaceuticals$39.19+2.51%−33.1%———$3.80BCompare
VKTXViking Therapeutics$27.97+7.21%−13.4%———$3.57BCompare
TNGXTango Therapeutics$23.18+0.04%−1.9%−100.0%——$3.91BCompare
DYNDyne Therapeutics$18.54+2.71%−1.6%———$3.46BCompare

News about Acadia Pharmaceuticals

All news →
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to DeclineZacks Investment Research · Oct 28, 2026▼ NegativeINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADGlobeNewswire Inc. · Oct 27, 2026▼ NegativeCan Nuplazid and Daybue Strengthen Acadia's Growth Prospects?Zacks Investment Research · Oct 13, 2026▲ PositiveAcadia's Daybue Patent Allowance Extends U.S. Protection to March 2041Zacks Investment Research · Sep 29, 2026▲ PositiveWhy Acadia Pharmaceuticals Stock Is Soaring TodayThe Motley Fool · Jun 26, 2026▲ Positive

Quick answers

What does Acadia Pharmaceuticals do?
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases.
What is ACAD's market cap?
$3.70B, based on the Nov 4 close of $21.47.
What is ACAD's P/E ratio?
9.7× trailing-twelve-month earnings of $380.48M.
Does Acadia Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ACAD is sold short?
9.1M shares, 7.1% of float, as of Oct 15, 2026.
What sector is ACAD in?
Healthcare, in the Pharmaceuticals industry.

About Acadia Pharmaceuticals

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

HQ: San Diego, CA798 employeesListed May 27, 2004acadia.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology